Zentalis : Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. Multiple mono and combo trials are ongoing/planned across the pipeline.
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Public, USA
Market Cap
1B +
1359 Broadway
Suite 1710
New York, NY 12065
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • Adam Levy, Senior Vice President of Investor Relations
  • Kim Blackwell, Dr., Chief Executive Officer
  • Melissa Epperly, Chief Financial Officer

Lead Programs

ZN-c3: WEE1i

Potentially first- and best-in class oral inhibitor

Indication Phase
Monotherapy & Combination studies (Multiple) 1/2

ZN-d5: BCL-2

Oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication Phase
Hematologic Malignancies and related disorders 1/2

BCL-xL Degrader

Solid Tumors and Hematologic Malignancies

Indication Phase
Solid Tumors and Heme Malignancies Pre-clinical

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Matrix Capital Management Co. LP 19.80 13,959,973 280.04 13F 6/30/23
Fidelity Management & Research Co. LLC 12.58 8,869,493 177.92 13F 6/30/23
Eventide Asset Management LLC 9.75 6,877,803 137.97 13F 6/30/23
Vanguard Group, Inc. (Subfiler) 6.78 4,782,483 95.94 13F 6/30/23
State Street Corp. 4.47 3,152,914 63.25 13F 6/30/23
Capital Research & Management Co. (International Investors) 4.44 3,127,758 62.74 13F 6/30/23
T Rowe Price Associates, Inc. (13F Subfiler) 3.76 2,648,978 53.14 13F 6/30/23
Avidity Partners Management LP 3.31 2,334,000 46.82 13F 6/30/23
T. Rowe Price Associates, Inc. (Investment Management) 3.30 2,323,771 46.61 Funds 8/31/23
BlackRock Fund Advisors 3.07 2,162,328 43.38 13F 6/30/23
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.